Square Launches Integrated, Omnichannel Solutions For Businesses in France
21.9.2021 10:00:00 EEST | Business Wire | Press release
Today Square, the globally trusted software, payments, and hardware solution for businesses of all sizes, launches in France. Following a successful Early Access Programme, now small businesses and large enterprises across France can access Square’s innovative ecosystem with the tools they need to start, run, grow, and adapt their businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005137/en/
Square Launches Integrated, Omnichannel Solutions For Businesses in France (Photo: Business Wire)
“I’ve been using Square’s products both on-site and online over the past few months and it has revolutionised how I run my business,” said Anne-Laure Fonrose, Founder of Tatie Nanna. “Having an integrated, omnichannel payment solution means our customers can pay in any way that suits them. It’s all been easy to set-up and run, the product looks great on site, and the connectivity is super-fast which helps avoid long queues. I’m proud to be using Square as we continue to grow our business.”
French businesses will now have access to a full stack of integrated business tools. Square’s suite of products are designed to seamlessly work with each other to save businesses time and money, reduce inefficiencies from managing multiple systems, and help sellers grow their businesses in the future. Additionally, Square offers fair, transparent, and merchant-friendly pricing for business software and payment processing without requiring any long-term contract or extra fees. Square takes care of fraud prevention, dispute management, security, and compliance at no additional cost. Square’s POS certification also enables merchants to comply with the “Loi anti-fraude TVA, 20181”. Businesses can access their funds as soon as the next working day and only pay a transaction fee when they accept a card or mobile payment.
“International growth has been a key priority this year, and we’re proud to officially launch in France as our third European market,” said Alyssa Henry, Executive Vice President at Square. “Sellers around the country will now be able to use our omnichannel ecosystem of products and services, allowing business owners to focus on running their business.”
“We are thrilled to expand Square’s solutions into France, helping merchants to run their entire business end-to-end with integrated software, hardware, and data analytics, while making it easier for them to take card payments,” said Jason Lalor, European Executive Director at Square. “French businesses can trust Square to be a fair, transparent, and innovative partner they can rely on to help them run their business and get back-on-track after times of uncertainty.”
French businesses can now sell online, in-person, or both with Square’s integrated suite of products, including:
-
Point of sale and payments software and hardware to suit any business: Square launches with two point of sale software products and three versatile payment terminals in France offering both mobile and brick & mortar businesses fully integrated POS software, reliable and secure payments acceptance, and one transparent processing rate of 1.65% for all card-present transactions. With no long-term contracts or monthly fees, the systems are designed for you and your employees to get started quickly.
- Square Point of Sale is the trusted solution used by business owners around the world to process payments, sell anywhere, and manage their customer base. With fast checkout flows, built-in customer management, and intuitive sales reporting, Square Point of Sale makes it easy to run a business customers love.
- Square for Restaurants helps businesses by offering an integrated set of industry-specific tools and POS for food and beverage merchants that would ordinarily require multiple vendors, all under one umbrella.
- Square Terminal, Square Stand, and Square Reader are versatile, easy-to-set-up devices. For a limited time, Square Terminal will be priced at 99 € (usually 165 €), Square Stand will be 79 € (usually 139 €), and Square Reader will be completely free (usually 19 €) – all available on Square Shop. This pricing is limited to one device per merchant.
- Square Online: Square’s fully integrated e-commerce platform that automatically syncs inventory and orders with any Square point of sale makes it seamless for any business to expand through omnichannel selling. Square Online supports sellers across a variety of verticals: from easily enabling click-and-collect for local business, to a QR code dining platform allowing diners to order and pay from their mobile device, to a full ecommerce website with social media integrations for retail. Square Online offers a feature-rich free plan as well as a variety of paid subscription plans and payment processing is competitively priced at 1.4% + 25c per transaction for EU cards.
-
Robust business tools to power operations: Square manages the behind-the-scenes details, giving time back to merchants to focus on running their business. Tools include:
- Online Checkout, to quickly sell online via embeddable buy buttons and payment links
- Virtual Terminal, to use your computer to take payments remotely
- Team Management, to streamline timecards and staffing
- Kitchen Display System, to expedite your kitchen operations – including delivery orders
- eGift Cards, to provide an additional way to reach customers
- Square Invoices will launch later this year to help businesses send professional, digital estimates and invoices and get paid faster
- Partner platform to unlock even more functionality: Square integrates with business tools like Prestashop, Wix, Bookeo and Deliverect to enable businesses to use Square seamlessly with third-party software that caters to their specific needs.
- Suite of API’s enabling developers to create solutions for sellers: Our APIs and SDKs enable developers to build custom applications that can seamlessly integrate with the rest of our ecosystem of products.
Businesses interested in learning more about getting started with Square can visit: https://squareup.com/fr
About Square, Inc.
Square, Inc. (NYSE: SQ) builds tools to empower businesses and individuals to participate in the economy. Sellers use Square to reach buyers online and in person, manage their business, and access financing. Individuals use Cash App to spend, send, store, and invest money. And TIDAL is a global music and entertainment platform that expands Square's purpose of economic empowerment to artists. Square, Inc. has offices in the United States, Canada, Japan, Australia, Ireland, Spain, Norway, and the UK.
1On 24 October 2018, the French Anti-Fraud Act1 (loi relative à la lutte contre la fraude, the Act) was published in the Official Journal (OJ). The Act was designed to strengthen the measures to fight against taxpayers’ failure to comply with their tax and social duties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005137/en/
Contact information
Daniela Karthaus
00353-896025037
press@squareup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
